Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

Journal of Diabetes Investigation

Volumn 2, Issue 3, 2011, Pages 210-217

  Kadowaki, Takashi ^a   Namba, Mitsuyoshi ^b   Imaoka, Takeshi ^c   Yamamura, Ayuko ^c   Goto, Wakana ^c   Boardman, Marilyn K ^c   Sowa, Hideaki ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Exenatide; Glycemic control; Japanese

Indexed keywords

BIGUANIDE; EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; PLACEBO; SULFONYLUREA;

ADULT; AGED; ANOREXIA; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC KETOACIDOSIS; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMACH DISCOMFORT; TREATMENT DURATION; VOMITING; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 79961065111     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00084.x     Document Type: Article

References (23)

1. Health, Labor and Welfare Association, Ministry of Health. Outline of the National Health and Nutrition Survey. Japan 2006. [In Japanese]. http://www.mhlw.go.jp/houdou/2008/04/dl/h0430-2c.pdf.
2. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev 2002; 18: S9-S13.
3. Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50: 583-589.
4. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
5. Nauck MA, Wollschläger D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 12: 1546-1553.
6. Li Y, Hansotia T, Yusta B, et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278: 471-478.
7. Triplitt CL. New technologies and therapeies in the management of diabetes. Am J Manag Care 2007; 13: S47-S54.
8. Kuroe A, Fukushima M, Usami M, et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003; 59: 71-77.
9. Kadowaki T, Namba M, Yamamura A, et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 2009; 56: 415-424.
10. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
11. Health, Labor and Welfare Association, Ministry of Health. Extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. Notification No.592 of the Pharmaceuticals and Cosmetic Division 1995. [In Japanese].
12. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628- 2635.
13. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
14. Zinman B, Hoogwerf BJ, Durán García S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2007; 146: 477-485.
15. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
16. Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005; 7: 467-477.
17. Gao Y, Yoon KH, Chuang LM, et al. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
18. The DECODE study group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
19. International Diabetes Federation: Guideline for Management of Postmeal Glucose. 2005; http://www.idf.org/webdata/docs/Guideline_PMG_final.pdf.
20. Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005; 34: 77-98.
21. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447.
22. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
23. Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 2010; 26: 1013-1022.